Inhibitory effects of N-(3,5-Dimethoxy-4-n-octyloxycinnamoyl)-N′-(3, 4-dimethylphenyl)piperazine (YIC-C8-434), an Acyl-CoA:Cholesterol O-acyltransferase inhibitor, on cholesterol esterification in the intestine and liver

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 8, 2003, Pages 1125-1128

  Ohishi, Kenji ^a   Sawada, Haruji ^a   Yoshida, Yasuto ^a   Yokoi, Wakae ^a   Hatano, Hiroshi ^a   Aiyama, Ritsuo ^a   Watanabe, Tsunekazu ^a   Yokokura, Teruo ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Acyl CoA:cholesterol O acyltransferase inhibitor; Cholesterol esterification; Hepatic cholesterol secretion; Intestinal cholesterol absorption; YIC C8 434

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL OLEATE; N (3,5 DIMETHOXY 4 OCTYLOXYCINNAMOYL) N' (3,4 DIMETHYLPHENYL)PIPERAZINE; OLEIC ACID; PHOSPHOLIPID; TRIACYLGLYCEROL; TRITIUM; TYLOXAPOL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; YIC C8 434; (N (3,5 DIMETHOXY 4 N OCTYLOXYCINNAMOYL) N' (3,4 DIMETHYLPHENYL)PIPERAZINE); (N-(3,5-DIMETHOXY-4-N-OCTYLOXYCINNAMOYL)-N'-(3,4-DIMETHYLPHENYL)PIPERAZINE); CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; CINNAMIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL ESTERIFICATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPOCHOLESTEROLEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; LIVER; LIVER CELL; LIVER CELL CARCINOMA; NONHUMAN; RAT; ANIMAL; CELL STRAIN CACO 2; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CACO-2 CELLS; CHOLESTEROL ESTERS; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINES; LIVER; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEROL O-ACYLTRANSFERASE;

EID: 2142701377     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.1125     Document Type: Article

References (17)

1. Brown M. S., Ho Y. K., Goldstein J. L., J. Biol. Chem., 255, 9344-9352 (1980).
2. Kannel W. B., Castelli W. P., Gordon T., McNamara P. M., Ann Intern Med., 74, 1-12 (1971).
3. Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA, 251, 351-364 (1984).
4. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., N. Engl J Med., 317, 1237-1245 (1987).
5. Suckling K. E., Stange E F., J Lipid Res , 26, 647-671 (1985).
6. Shepherd J., Packard C. J., Trends Pharmacol. Sci., 9, 326-329 (1988).
7. Sliskovic D. R., White A. D., Trends Pharmacol. Sci., 12, 194-199 (1991).
8. Ohishi K., Aiyama R., Hatano H., Yoshida Y., Wada Y., Yokoi W., Sawada H., Watanabe T., Yokolcuia T., Chem. Pharm Bull., 49, 830-839 (2001).
9. Itokawa H., Aiyama R., Ikuta A., Phytochemistry, 21, 241-243 (1982).
10. Helgerud P., Saarem K., Norum K. R., J. Lipid Res., 22, 271-277 (1981)
11. Zilversmit D. B., Proc. Soc Exp Biol Med., 140, 862-865 (1972).
12. Robertson R. P., Gavareski D. J., Henderson J. D., Porte D., Jr., Bierman E. L., J. Clin. Invent., 52, 1620-1626 (1973).
13. Chang T. Y., Chang C. C. Y., Cheng D., Annu. Rev. Biochem., 66, 613-638 (1997).
14. Fielding C. J., Renston J P., Fielding P. E., J. Lipid Res , 19, 705-711 (1978).
15. Sakuma Y., Hagihara H , Ohne K., Nagayoshi A., Mutoh S., Ito Y., Notsu Y., Okuhara M., Jpn. J. Pharmacol., 70, 35-41 (1996)
16. Azuma Y., Kawasaki T., Ikemoto K , Obata K., Ohno K., Sajiki N., Yamada T., Yamasaki M., Nobuhara Y., Jpn. J. Pharmacol., 78, 355-364 (1998).
17. Kaneko K., Uchida K., Kobayashi T., Miura K., Tanokura K., Hoshino K., Kato I., Onoue M., Yokokura T., Toxicol Sci., 64, 259-268 (2001).